Epitalon

Epitalon (also written Epithalon; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide with molecular formula C14H22N4O9 and molecular weight 390.35 g/mol. It was designed to replicate the bioactive core of epithalamin, a peptide fraction isolated from bovine pineal gland tissue, based on its amino acid composition.

Its principal proposed mechanism is induction of telomerase activity in somatic cells that ordinarily lack expression of this enzyme. In telomerase-negative human fetal fibroblasts, Khavinson et al. (2003, PMID 12937682) reported that Epitalon prompted expression of the catalytic subunit hTERT, elevated enzymatic telomerase activity, and produced measurable telomere elongation, apparently through promoter activation of the TERT gene. A 2025 study in Biogerontology by Al-dulaimi et al. (DOI 10.1007/s10522-025-10315-x) independently replicated telomere elongation across multiple human cell lines and identified that Epitalon activates the alternative lengthening of telomeres (ALT) pathway in cancer cell lines while relying on telomerase upregulation in normal epithelial and fibroblast cells, indicating cell-type-specific mechanisms. Note that a correction to the figures in that 2025 paper was subsequently published.

Additional proposed mechanisms include: • Binding to methylated cytosine residues in DNA and to the linker histone H1, suggesting epigenetic regulatory effects on gene expression • Upregulation of melatonin synthesis, possibly via signaling effects on the pineal gland • Modulation of interleukin-2 mRNA levels • Enhancement of antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase) • Inhibition of matrix metalloproteinase-9 (MMP9) in aging skin fibroblasts

Despite over two decades of investigation, the precise molecular mechanism remains incompletely characterized, and a 2025 narrative review (PMC11943447) noted the multiplicity of reported effects without a unified mechanistic model.

Clinical and preclinical research on Epitalon has been conducted almost entirely by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The concentration of virtually all controlled trials within a single research group, without independent replication, is the central limitation of the evidence base.

In vitro, the Khavinson group reported that Epitalon induced telomerase expression and extended cellular lifespan in human fetal fibroblasts, with treated cells reaching proliferative passage 44 compared to controls reaching the Hayflick limit at passage 34 (PMID 15455129). The 2025 Biogerontology study by Al-dulaimi et al. (DOI 10.1007/s10522-025-10315-x), using breast cancer lines 21NT and BT474 as well as normal epithelial and fibroblast cells, provided the first substantive independent in vitro confirmation of dose-dependent telomere elongation; a correction to figures in that paper was later published.

In humans, the most cited outcomes data come from a 12-year randomized controlled trial in 79 elderly patients with coronary artery disease and accelerated cardiovascular aging (Korkushko et al., PMID 17426848; extended 15-year follow-up at PMID 22451889). Patients received biannual courses of epithalamin alongside standard care. After 12 years, overall mortality in the treated group was reported as 28% lower than controls, with approximately 50% lower cardiovascular-specific mortality. Critically, this trial used epithalamin (a crude bovine pineal gland extract containing multiple peptides), not synthetic Epitalon (AEDG); these are closely related but chemically distinct preparations.

A separate study in 162 patients aged 18-72 with retinitis pigmentosa (Khavinson et al., PMID 12195242) used parabulbar injection of synthetic Epitalon at 5 µg per eye for 10 consecutive days and reported visual acuity improvement averaging 0.15-0.20 in 90% of cases, with no adverse effects. A circadian rhythm study in 75 women administered 0.5 mg/day sublingual Epitalon for 20 days and found a 1.6-fold increase in melatonin synthesis and doubled Cry2 expression (p less than 0.05).

No multi-center, independently preregistered, adequately powered randomized controlled trials have been conducted, and no regulatory agency has approved Epitalon for any indication.

Typical dosage: 5-10 mg (cycle).

Dosing in the published literature varies significantly by indication and compound form. In the Khavinson long-term coronary patient trials, epithalamin (pineal extract, not synthetic AEDG) was administered as intramuscular injections of 10 mg per session across 5 treatment days with 3-day intervals between each dose, repeated every 6 months. In the retinitis pigmentosa trial (PMID 12195242), synthetic Epitalon (AEDG) was given as parabulbar injections of 5 µg per eye for 10 consecutive days. A melatonin/circadian study used sublingual administration of 0.5 mg per day for 20 days.

In off-label community and biohacker use, where Epitalon is sold as a research peptide not approved for human therapeutic use, reported protocols include:

• 5-10 mg per day by subcutaneous or intramuscular injection for 10-20 consecutive days • Courses repeated 2-3 times per year, separated by washout periods of 4-6 months • Evening administration is sometimes recommended given reported effects on melatonin and circadian rhythm • Reconstitution typically performed with bacteriostatic water

Intranasal and oral routes have been explored in animal studies. Oral dosing in humans appears in anecdotal reports but is not supported by published clinical data on bioavailability or efficacy.

This information is provided for educational purposes only and does not constitute medical advice. Epitalon is not approved by the FDA, EMA, or any comparable regulatory agency for human therapeutic use. Consult a qualified, licensed healthcare professional before considering any experimental peptide compound.

Lyophilized (before reconstitution)

Multiple vendor sources cite roughly 24 months frozen (−20°C) for Epitalon (also spelled Epithalon) lyophilized powder. Refrigerated (2–8°C) storage is acceptable for shorter active-use windows. Keep dry, sealed, and away from light.

Reconstituted

Commonly cited at ~28–30 days refrigerated (2–8°C) in bacteriostatic water. Never freeze a reconstituted vial. This is a vendor-derived convention rather than a peptide-specific stability study — the window traces to the 0.9% benzyl alcohol preservative's antimicrobial validation, not to an Epitalon-specific assay. See the Storage & handling primer for context.

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

Reported combinations draw almost entirely from anecdotal community sources and the Khavinson laboratory's multi-peptide protocols. No independently conducted combination trials exist.

The most documented combination in the Khavinson literature pairs Epitalon with Thymalin, a thymic peptide bioregulator. In one observational cohort study (n=266), annual administration of both peptides together was associated with a reported 4.1-fold reduction in mortality over 6 years, compared to 1.6-1.8-fold for either agent alone. This finding has not been independently confirmed and must be interpreted with caution given the source limitations described throughout.

Within biohacker and longevity-focused communities, Epitalon is anecdotally combined with the following compounds, all without controlled trial evidence for the combination:

• GHK-Cu (copper tripeptide): claimed synergistic support for collagen synthesis, tissue repair, and reduction of oxidative stress — anecdotal only • TB-500 (thymosin beta-4 fragment): for reported recovery and anti-inflammatory effects — anecdotal only • Semax or Selank (Russian neuropeptides): for claimed cognitive enhancement alongside circadian normalization — anecdotal only, no combination clinical data

No controlled study has evaluated any of these combinations for safety, pharmacokinetic interaction, or efficacy.

Epitalon is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed Epitalon from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place Epitalon on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very well-tolerated. Minimal side effects during cycles

Published clinical trials by the Khavinson group report no serious adverse events across multiple studies, including over a 12-year follow-up period. The retinitis pigmentosa trial (n=162, PMID 12195242) specifically reported no adverse effects from synthetic Epitalon given by parabulbar injection. These Khavinson-group trials represent the only controlled safety data available, and they originate from a single research group without independent replication.

In off-label community use, the most commonly reported adverse effects are mild injection site reactions (transient redness, swelling, localized pain). Less frequently reported effects include mild headache, dizziness, and transient gastrointestinal discomfort; none of these have been systematically characterized in any controlled study.

A theoretical safety concern exists regarding telomerase activation: constitutive telomerase activity is a hallmark of the majority of human cancers, and chronic stimulation of this pathway could theoretically facilitate oncogenesis or promote growth of subclinical malignancies. Existing rodent data did not show increased tumor incidence and in some studies reported reduced spontaneous tumor rates; however, human study populations are too small and follow-up periods too short to address this risk adequately. A 2025 systematic review (PMC11943447) explicitly stated that information regarding critical safety issues, including carcinogenic potential, is currently missing and called for dedicated toxicology studies.

No pharmacokinetic data exist for synthetic Epitalon in humans, and no systematic drug interaction studies have been conducted. As an unregulated compound sold without standardization, purity and potency vary substantially between commercial suppliers. Epitalon has no regulatory-approved prescribing information. Individuals with a current or prior diagnosis of malignancy are commonly advised to avoid the compound as a precautionary measure, though no controlled evidence directly supports this contraindication.